Skip to main content

Advertisement

SpringerLink
Log in

Clinical and pathological characteristics of screen-detected versus clinically diagnosed prostate cancer in Nanjing, China

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Previous studies have suggested that implementation of PSA screening in China is of crucial importance. This study compared clinical and pathological characteristics of screen-detected and clinically diagnosed prostate cancers and evaluated the effectiveness of PSA screening for early detection of prostate cancer in Nanjing. Between July 2004 and December 2005, 8,562 men aged ≥50 years were included for PSA screening. Participants with serum PSA ≥4.0 ng/ml were recommended for transrectal ultrasonography (TRUS)-guided prostate needle biopsy (TRNB). During the same period, 82 consecutive clinically diagnosed prostate cancers were included as controls. The clinical and pathological features of the screened versus clinically diagnosed cancers were evaluated. A total of 719 (8.4%) of screened men had PSA levels ≥4.0 ng/ml. Biopsy was performed in 295 men, and 58 prostate cancers were detected. The biopsy rate, positive predictive value (PPV), and detection rate were 41.0, 19.7, and 0.68%, respectively. More screened patients were found with PSA levels <20 ng/ml (55.2 vs. 22.4%, P < 0.001), Gleason scores <7 (60.3 vs. 34.1%, P = 0.002), organ-confined tumors (87.9 vs. 26.8%, P < 0.001), and opportunities for radical prostatectomy (50.0 vs. 18.3%, P < 0.001) than that in clinically diagnosed patients. PSA screening is effective for early detection of prostate cancer in Chinese elderly men. Favorable PSA levels, Gleason scores, clinical stages, and chances for radical prostatectomy are associated with PSA screening. Further studies are needed to evaluate the effect of screening on treatment outcomes and mortality of prostate cancer in Chinese.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AJCC:

American Joint Committee on Cancer

CT:

Computed tomography

DRE:

Digital rectal examination

ERSPC:

European randomized study of screening for prostate cancer

LUTS:

Lower urinary tract symptoms

MRI:

Magnetic resonance imaging

PLCO:

Prostate, lung, colorectal and ovarian

PPV:

Positive predictive value

PSA:

Prostate-specific antigen

SD:

Standard deviation

TRNB:

Transrectal ultrasonography-guided prostate needle biopsy

TRUS:

Transrectal ultrasonography

UICC:

Union Internationale Contre le Cancer

References

  1. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147:841–5.

    PubMed  CAS  Google Scholar 

  2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–61.

    Article  PubMed  CAS  Google Scholar 

  3. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147:846–51. (discussion 51–52).

    PubMed  CAS  Google Scholar 

  4. Imai K, Zinbo S, Shimizu K, Yamanaka H, Kumasaka F, Sato Z. Clinical characteristics of prostatic cancer detected by mass screening. Prostate. 1988;12:199–207.

    Article  PubMed  CAS  Google Scholar 

  5. Makinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, et al. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen. Clin Cancer Res. 2003;9:2435–9.

    PubMed  Google Scholar 

  6. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol. 2005;174:121–5.

    Article  PubMed  Google Scholar 

  7. Paquette EL, Sun L, Paquette LR, Connelly R, McLeod DG, Moul JW. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology. 2002;60:756–9.

    Article  PubMed  Google Scholar 

  8. Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol. 2006;24:465–71.

    PubMed  Google Scholar 

  9. Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL. Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care. 2007;45:154–9.

    Article  PubMed  Google Scholar 

  10. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60–7.

    Article  PubMed  CAS  Google Scholar 

  11. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002;90:162–73.

    Article  PubMed  CAS  Google Scholar 

  12. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005;41:834–45.

    Article  PubMed  Google Scholar 

  13. Gu F. Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J (Engl). 2003;116:1391–3.

    Google Scholar 

  14. Gao HW, Li YL, Wu S, Wang YS, Zhang HF, Pan YZ, et al. Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl. 2005;7:159–63.

    Article  PubMed  Google Scholar 

  15. Kuwahara M, Tochigi T, Kawamura S, Ogata Y, Xu N, Wang H, et al. Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China. Urology. 2003;61:137–41.

    Article  PubMed  Google Scholar 

  16. Li X, Tsuji I, Kuwahara M, Zhang H, Wang H, Zhang L, et al. Mass screening of prostate cancer in Changchun City of China. Int Urol Nephrol. 2004;36:541–8.

    Article  PubMed  Google Scholar 

  17. Zhang HF, Wang HL, Xu N, Li SW, Ji GY, Li XM, et al. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen. Chin Med J (Engl). 2004;117:67–70.

    Google Scholar 

  18. Chuang AY, Chang SJ, Horng CF, Tsou MH. Study of prostate cancer pathologic features in Chinese populations. Urology. 2007;69:915–20.

    Article  PubMed  Google Scholar 

  19. Peyromaure M, Debre B, Mao K, Zhang G, Wang Y, Sun Z, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol. 2005;174:1794–7.

    Article  PubMed  Google Scholar 

  20. Uchida K, Takeshima H, Akaza H, Ono Y. Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system. Jpn J Clin Oncol. 2000;30:95–100.

    Article  PubMed  CAS  Google Scholar 

  21. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer. 1994;74:104–14.

    Article  PubMed  CAS  Google Scholar 

  22. Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr. 1988;7:15–8.

    PubMed  Google Scholar 

  23. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 1996;48:234–9.

    Article  PubMed  CAS  Google Scholar 

  24. Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran. Int J Urol. 2007;14:406–11.

    Article  PubMed  Google Scholar 

  25. Ku JH, Ahn JO, Lee CH, Lee NK, Park YH, Byun SS, et al. Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity. Urology. 2002;60:475–9.

    Article  PubMed  Google Scholar 

  26. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996;335:304–10.

    Article  PubMed  CAS  Google Scholar 

  27. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol. 1995;75:347–53.

    Article  PubMed  CAS  Google Scholar 

  28. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract. 2003;16:95–101.

    Article  PubMed  Google Scholar 

  29. Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005;97:433–8.

    Article  PubMed  Google Scholar 

  30. Bunker CH, Patrick AL, Konety BR, Dhir R, Brufsky AM, Vivas CA, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev. 2002;11:726–9.

    PubMed  Google Scholar 

  31. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, et al. Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer. 2000;36:1322–35.

    Article  PubMed  CAS  Google Scholar 

  32. Maattanen L, Hakama M, Tammela TL, Ruutu M, Ala-Opas M, Juusela H, et al. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer. 2007;96:56–60.

    Article  PubMed  CAS  Google Scholar 

  33. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology. 1998;52:444–8. (discussion 8–9).

    Article  PubMed  CAS  Google Scholar 

  34. Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Int J Urol. 2005;12:662–7.

    Article  PubMed  Google Scholar 

  35. Robbins AS, Yin D, Parikh-Patel A. Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995–2004. Am J Epidemiol. 2007;166:71–8.

    Article  PubMed  Google Scholar 

  36. Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW. Prostate specific antigen testing in men older than 75 years in the United States. J Urol. 2006;176:511–4.

    Article  PubMed  Google Scholar 

  37. Pinsky PF, Andriole GL, Kramer BS, Hayes RB, Prorok PC, Gohagan JK. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol. 2005;173:746–50. discussion 50-1.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Amanda Cui and Benson Wallace at the Enjoyabc Company for their valuable advices on the manuscript. A special thank you goes to all the participants for their time and effort in this study.

Author information

Authors and Affiliations

  1. Department of Urology, First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China

    LiXin Hua, Bin Xu, NingHan Feng, Gong Cheng, JieXiu Zhang, NingHong Song, Wei Zhang, Jie Yang, JianGang Chen, YuanGeng Sui & HongFei Wu

  2. Department of Urology, Jiangsu Provincial Research Institute of Geriatrics, Nanjing, China

    Di Qiao

Authors
  1. LiXin Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Di Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. NingHan Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gong Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. JieXiu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. NingHong Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jie Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. JianGang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. YuanGeng Sui
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. HongFei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to LiXin Hua or HongFei Wu.

Additional information

LiXin Hua, Di Qiao, and Bin Xu contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hua, L., Qiao, D., Xu, B. et al. Clinical and pathological characteristics of screen-detected versus clinically diagnosed prostate cancer in Nanjing, China. Med Oncol 28, 357–364 (2011). https://doi.org/10.1007/s12032-009-9409-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9409-3

Keywords

Search

Navigation